Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low on Monday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 1445 shares trading hands. The stock had previously closed at C$0.05.
Resverlogix Trading Up 12.5 %
The company has a market capitalization of C$8.91 million, a P/E ratio of -2.23 and a beta of 0.71. The company has a fifty day simple moving average of C$0.05 and a two-hundred day simple moving average of C$0.05. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Read More
- Five stocks we like better than Resverlogix
- How to Invest in Insurance Companies: A Guide
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Investing In Preferred Stock vs. Common Stock
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
